Welcome to our dedicated page for Fosun International news (Ticker: FOSUF), a resource for investors and traders seeking the latest updates and insights on Fosun International stock.
Fosun International Limited (FOSUF) generates a diverse stream of news that reflects its role as a global innovation-driven consumer group active in health, cultural tourism, consumption, financial services, and insurance. News coverage often focuses on how Fosun advances its innovation and globalization strategy across these areas.
Investors and observers following FOSUF can expect regular updates on topics such as interim and annual business results, strategic portfolio adjustments, and developments in core subsidiaries. In the health segment, news frequently highlights progress in innovative drugs, biopharmaceutical research, medical devices, and international regulatory milestones achieved by companies within the Fosun ecosystem.
In cultural tourism and consumption, Fosun-related news includes information on tourism projects, resort operations, and cultural initiatives that promote experiential consumption and international cultural exchange. In financial services and insurance, articles may cover credit ratings, international expansion of insurance operations, and asset servicing activities that align with the group’s asset-light strategy.
Fosun also appears regularly in ESG and sustainability news, including updates on corporate sustainability assessment scores, climate-related disclosures, and social responsibility programs such as rural healthcare support and contributions to global public health challenges. This news page aggregates such announcements, allowing readers to track how Fosun communicates its performance, strategic focus, and corporate citizenship over time.
By monitoring the FOSUF news feed on Stock Titan, users can review company-issued releases and related coverage that shed light on Fosun’s evolving business mix, geographic reach, and emphasis on innovation, globalization, and ESG practices.
Fosun International (OTC:FOSUY) presented its H1 2025 interim results, highlighting significant achievements in innovation and global expansion. The company reported total revenue of RMB87.28 billion, with overseas revenue accounting for 53% of total revenue. The Group's industrial operation profit reached RMB3.15 billion, while profit attributable to owners was RMB661.2 million.
The company's four core subsidiaries - Fosun Pharma, Yuyuan, Fosun Insurance Portugal, and Fosun Tourism Group - contributed 73% of total revenue at RMB63.61 billion. Management emphasized its focus on innovation, particularly in biopharmaceuticals, and its commitment to debt reduction, targeting interest-bearing debt of RMB60 billion or less while maintaining a current healthy debt-to-capital ratio of 53%.
Fosun International (OTC:FOSUY) Chairman Guo Guangchang outlined the company's strategic vision during its 2025 interim results presentation, emphasizing continued investment in biopharmaceuticals and focus on established advantageous sectors. The company has made significant breakthroughs in its pharmaceutical segment, with a robust pipeline of innovative drugs including Henlius products and Fosun Kite's CAR-T therapy.
Highlighting Fosun's commitment to global expansion, Guangchang emphasized the company's dedication to building global R&D, clinical, and sales capabilities. The chairman noted that establishing competitive strength requires long-term investment, citing Henlius's RMB10 billion investment over 15 years and the recent profitability of its insurance ventures.
The company maintains its vision of helping people live healthily to age 121, with a particular focus on making cancer curable through comprehensive treatment approaches combining drugs, devices, and multi-molecule therapies.
Fosun International (OTC:FOSUY) released its 2025 interim results, reporting total revenue of RMB87.28 billion and profit attributable to owners of RMB661.2 million. The company's four core subsidiaries generated RMB63.61 billion in revenue, representing 73% of total revenue.
Key highlights include RMB3.6 billion investment in technology and innovation, with significant breakthroughs in innovative drugs, particularly HLX43's global Phase II clinical trials. Overseas revenue reached RMB46.67 billion, accounting for 53% of total revenue. The company maintained a healthy debt ratio of 53% and received a "Stable" outlook from S&P.
Notable achievements include Fosun Pharma's 38.96% profit growth, Fosun Insurance Portugal's 27.6% net profit increase, and FTG's record business volume of RMB9.53 billion with 42% adjusted net profit growth year-on-year.
Fidelidade (FOSUY), a core subsidiary of Fosun International, has received an 'A' rating with stable outlook from Standard & Poor's (S&P) for both its insurance and reinsurance operations. This follows Fitch's A+ rating upgrade in September 2024, marking Fidelidade as the highest-rated Portuguese company.
The company demonstrated strong performance in 2024 with 12.6% growth in insurance revenues and net income of EUR173.5 million. Fidelidade maintains a 30% market share in Portugal and has expanded internationally across Europe, Africa, Latin America, and Asia, with international operations now representing 30% of total premiums. The company's solid financial position is reflected in its Solvency II ratio of 194% at year-end 2024.
[ "Received 'A' rating from S&P and A+ rating from Fitch", "Strong 12.6% growth in insurance revenues for 2024", "Robust Solvency II ratio of 194%", "Significant international diversification with 30% of premiums from international operations", "Leading market position with 30% share in Portugal" ]Fosun International (OTC:FOSUY) has achieved significant recognition in its ESG performance, with its FTSE Russell ESG rating upgraded to 3.9 in 2025, surpassing both the global industry average of 2.6 and the national average of 2.0.
The company secured perfect scores of 5.0 in Environmental Supply Chain, Anti-Corruption, and Risk Management. Fosun has maintained its position in the FTSE4Good Index Series for four consecutive years and holds notable ratings including an MSCI ESG rating of AA, HSI ESG rating of AA-, and ranks in the top 5% among global peers in S&P Global's Corporate Sustainability Assessment.
Fosun International Limited (OTC:FOSUY) has completed the sale of its 99.743% stake in German private bank Hauck Aufhäuser Lampe Privatbank AG (HAL) for EUR670 million. The transaction, completed on June 30, 2025, delivered a double-digit internal rate of return (IRR) for Fosun.
While divesting HAL's banking business, Fosun retains full ownership of Hauck & Aufhäuser Fund Services S.A. (HAFS), its valuable asset servicing business that manages over EUR100 billion in assets across Luxembourg, Ireland, and German-speaking regions. HAFS will continue collaborating with HAL for fund administration services.
This strategic move aligns with Fosun's asset-light operating strategy and focus on core businesses. The company plans to increase investments in key sectors including biopharmaceuticals, cultural tourism, insurance, and healthcare, while pursuing its goal of achieving RMB10 billion in annual profits.
Fosun International (OTC:FOSUY) has received five prestigious awards from Corporate Governance Asia, including recognition for its Co-CEOs and corporate sustainability efforts. Executive Directors and Co-CEOs Chen Qiyu and Xu Xiaoliang were both honored with Asia's Best CEO awards, while the company secured the Sustainable Asia Award 2025, Best Environmental Responsibility Award, and Best Corporate Communications Award.
The company has demonstrated significant achievements in ESG initiatives, maintaining an MSCI ESG rating of AA and ranking in the top 5% among global peers in S&P Global's Corporate Sustainability Assessment. Fosun has committed to reaching carbon neutrality by 2050 and achieving peak carbon emissions by 2028.
In healthcare innovation, the company reported that its drug HANSIZHUANG received European Union approval in early 2025 as the first PD-1 innovative drug for first-line treatment of extensive-stage small cell lung cancer. Additionally, Fosun's artesunate injection has treated over 80 million severe malaria patients globally, while its CAR-T cell therapy has benefited more than 800 lymphoma patients in mainland China.
Fosun International (FOSUY) has released its 2024 ESG Report and third Climate Information Disclosures Report, highlighting its commitment to sustainable development. The company maintained an MSCI ESG rating of AA and ranked in the top 5% among global peers in S&P Global's Corporate Sustainability Assessment.
The company has established concrete climate goals, aiming to peak carbon emissions by 2028 and achieve carbon neutrality by 2050. Notable achievements include completing a USD888 million sustainability-linked syndicated loan and maintaining LEED Platinum certification for the Bund Finance Center in Shanghai.
In healthcare innovation, Fosun's anticancer drug HANSIZHUANG received EU approval for small cell lung cancer treatment, while their artesunate injection has treated over 80 million severe malaria patients globally. The company's total assets reached RMB796.5 billion as of December 2024.
Nanyang Commercial Bank (NCB) and Fosun International (HKEX: 00656) have signed a strategic cooperation agreement on April 24, 2025, marking a new milestone in their 15-year partnership that began in 2010. The agreement aims to strengthen their financial collaboration, with NCB providing comprehensive banking services to support Fosun's future development.
NCB will leverage its cross-border operations expertise while integrating with Fosun's global presence in over 35 countries. The partnership focuses on developing products and services based on complementary advantages and mutual benefits. The agreement was signed at NCB's Hong Kong headquarters, attended by key executives from both companies including Sun Jiandong, Wang Qunbin, and Gong Ping.